pharma · EBV-induced Lymphomas · Coronary Artery Disease
Evidence Based Cataract
Evidence Based Cataract Study Group
Evidence Based Cataract is a pharma organization headquartered in THOUSAND OAKS, CA, CN. Primary therapeutic focus areas include EBV-induced Lymphomas, Coronary Artery Disease, Primary Progressive Multiple Sclerosis, Lup
THOUSAND OAKS, CA, CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- THOUSAND OAKS, CA, CN
- Programs
- 10
- Drugs
- 8
- Patents
- 10
Tabelecleucel
Phase 2 · mab · Nasopharyngeal Carcinoma
Tabelecleucel for Nasopharyngeal Carcinoma is a Phase 2 program (mab) at Evidence Based Cataract Study Group with 1 ClinicalTrials.gov record(s).
Internal code ATA129-NPC-202
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Evidence Based Cataract Study Group
- Phase
- Phase 2
- Modality
- mab
- Indication
- Nasopharyngeal Carcinoma
- Status
- terminated
- Trials
- 1